Physician profile
Colin Strack
NPI 1003274192
$3,162.19
in general payments reported to CMS, 2019-2025
24 companies · $926 in 2025
The $926 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $382 · 2023: $972 · 2024: $781 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618 · Education: $59.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.33 |
| Education | $59.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $880.17 | 2021-2025 | |
| Gilead Sciences, INC. | $348.58 | 2021-2025 | |
| Janssen Biotech, INC. | $309.60 | 2022-2025 | Stelara, Remicade, Simponi Aria |
| Celgene Corporation | $288.21 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $265.02 | 2022-2025 | Dupixent |
| Genzyme Corporation | $207.47 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.65 | 2023-2025 | Entyvio |
| Pfizer INC. | $125.07 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.33 | 2022-2024 | Xifaxan |
| Ardelyx, INC. | $62.99 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $52.58 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $46.91 | 2022-2025 | |
| Lilly USA, LLC | $40.21 | 2024-2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.19 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $37.09 | 2022-2023 | Linzess |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $30.68 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $28.32 | 2025 | Vegzelma |
| Echosens North America, INC. | $28.16 | 2024 | Fibroscan |
| Enterra Medical, INC. | $27.02 | 2024 | |
| Organon LLC | $25.55 | 2024 | |
| Novo Nordisk INC | $20.81 | 2025 | Wegovy |
| Amgen INC. | $20.76 | 2023 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Ferring Pharmaceuticals INC. | $12.71 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Strack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.